BioFactura's BFI-751, a Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study

Frederick, Maryland (PRWEB) October 14, 2022 -- BioFactura Inc. has announced today the completion of the pivotal pharmacokinetic comparability clinical trial

Related Keywords

Australia ,New Zealand ,Darryl Sampey ,Ustekinumab Biosimilar ,Jeffreyn Hausfeld ,Biofactura Inc ,Confidence Interval ,Chief Medical Officer ,Stablefast Biomanufacturing Platform ,Press Release ,